Compositions and methods for cleaning nasal cavities
Compositions and methods for cleaning nasal cavities are provided. Representative compositions include an active agent having a quaternary ammonium salt and a pharmaceutically acceptable carrier suitable for intranasal delivery. The compositions are formulated to reduce odors without triggering non-allergic rhinitis when delivered intranasally. The methods include cleaning the nasal cavities of a mammal by nasally delivering to the mammal a composition including a cleaning agent and a pharmaceutically acceptable carrier.
1 . A composition for cleaning nasal cavities comprising:
an active agent consisting essentially of a quaternary ammonium salt and a pharmaceutically acceptable carrier suitable for intranasal delivery, wherein the composition is formulated to reduce odors without triggering non-allergic rhinitis when delivered intranasally.
2 . The composition according to claim 1 , wherein the quaternary ammonium salt is chosen from the at least one quaternary ammonium salt of the following formula:
wherein N has a valency of 5;
R 1 , R 2 , R 3 , R 4 are the same or different and are independently chosen from H, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group; and
X is an anion, preferably a halogen:
3 . The composition according to claim 2 , wherein two or more of R 1 , R 2 , R 3 , and R 4 share at least one chemical bond.
4 . The composition according to claim 2 , further comprising a desensitizing agent.
5 . The composition according to claim 2 , further comprising at least one of a mucolytic agent, an antibiotic, a flavoring agent, and combinations thereof.
6 . The pharmaceutical composition according to claim 2 , wherein said carrier includes a component chosen from a buffer to maintain a physiological pH of said composition, a pharmaceutically acceptable thickening agent, a humectant, a pharmaceutically acceptable surfactant, and combinations thereof.
7 . The pharmaceutical composition according to claim 2 , further comprising at least one pharmaceutical excipients.
8 . The pharmaceutical composition according to claim 7 , further comprising a pharmaceutically acceptable preservative.
9 . The pharmaceutical composition according to claim 6 , wherein said buffer is chosen from at least one of acetate, citrate, borate, phosphate buffers, and combinations thereof.
10 . The pharmaceutical composition according to claim 6 , wherein said thickening agent is chosen from at least one of methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and mixtures thereof.
11 . The pharmaceutical composition according to claim 6 , wherein said humectant is chosen from at least one of sorbitol, propylene glycol, glycerol, and mixtures thereof.
12 . The pharmaceutical composition according to claim 6 , wherein said surfactant is chosen from at least one of polyoxyethylene derivatives, fatty acid partial esters of sorbitol anhydrides, and combinations thereof.
13 . The pharmaceutical composition according to claim 6 , wherein said surfactant is chosen from at least one of polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxyethylene alkyl ethers, polyoxyethylene castor oils, polyglycolyzed glycerides, transesterified and (poly)ethoxylated oils, sorbitan fatty acid esters, poloxamers, poloxamines, fatty acids salts, bile salts, alkylsulfates, lecithins, mixed micelles of bile salts and lecithins, sugar esters, and mixtures thereof.
14 . The pharmaceutical composition according to claim 6 , wherein said surfactant is chosen from at least one of anionic, cationic, nonionic surfactants, and combinations thereof.
15 . A method of cleaning nasal cavities in a mammal comprising nasally delivering to the mammal an active agent consisting essentially of a non-alcoholic cleaning agent and a pharmaceutically acceptable carrier suitable for intranasal delivery, wherein said composition is formulated to not trigger non-allergic rhinitis.
16 . The method according to claim 15 , wherein said carrier comprises a buffer to maintain the pH of said composition, a pharmaceutically acceptable thickening agent, a humectant, a flavoring agent, a pharmaceutically acceptable surfactant, and combinations thereof.
17 . The method according to claim 16 , further comprising at least one pharmaceutical excipients.
18 . The method according to claim 17 , further comprising a pharmaceutically acceptable preservative.
19 . The method according to claim 16 , wherein said buffer is chosen from at least one of acetate, citrate, phosphate buffers, and combinations thereof.
20 . The method according to claim 16 , wherein said thickening agent is chosen from at least one of methyl cellulose, xantham gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and mixtures thereof.
21 . The method according to claim 16 , wherein said humectant is chosen from at least one of sorbitol, propylene glycol, glycerol, and mixtures thereof.
22 . The method according to claim 16 , wherein said surfactant is chosen from at least one of polyoxyethylene derivatives, fatty acid partial esters of sorbitol anhydrides, and combinations thereof.
23 . The method according to claim 16 , wherein said surfactant is chosen from at least one of polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polyoxyethylene alkyl ethers, polyoxyethylene castor oils, polyglycolyzed glycerides, transesterified and (poly)ethoxylated oils, sorbitan fatty acid esters, poloxamers, poloxamines, fatty acids salts, bile salts, alkylsulfates, lecithins, mixed micelles of bile salts and lecithins, sugar esters, and mixtures thereof.
24 . The method according to claim 16 , wherein said surfactant is chosen from at least one of anionic, cationic, and nonionic surfactants.
25 . The method of claim 15 , wherein the dosage rate of the composition administered to a mammal is in an amount from 1 mg to about 10 g.
26 . The method of claim 15 , wherein the composition contains concentrations of a non-alcoholic cleaning agent in a range from about 0.001% to about 10% by weight.
27 . The method of claim 15 , wherein the administration rate comprises administering said composition at a rate of about once daily to about 4 times per day.
28 . A composition for treating non-allergenic rhinitis comprising an active agent consisting essentially of a non-alcoholic cleaning agent and a pharmaceutically acceptable carrier suitable for intranasal delivery,
wherein the composition is formulated to reduce odors without any flavoring agent or scented substance, and
wherein the composition is formulated not to trigger non-allergic rhinitis when delivered intranasally.
29 . A composition for treating non-allergenic rhinitis comprising an active agent, the active agent consisting of a non-alcoholic cleaning agent and a pharmaceutically acceptable carrier suitable for intranasal delivery,
wherein the composition is formulated to reduce odors without any flavoring agent or scented substance, and
wherein the composition is formulated not to trigger non-allergic rhinitis when delivered intranasally.